Search clinical trials for: New Cluster of Differentiation Antigen 19-chimeric Antigen Receptor T Cells

Total 497842 results

Second Military Medical University

Unknown

Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia

Recurrent B-Cell Tumor | Refractory B-Cell Tumor

China
John Lister
Miltenyi Biotec, Inc.; Lentigen Technology, Inc.; AHN (Allegheny Health Network)...

Recruiting

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | B Acute Lymphoblastic Leukemia | B-Cell Lymphoma | Transformed Lymphoma

United States
National Cancer Institute (NCI)

Completed

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Lymphoma, B-Cell | Lymphoma, Non-hodgkins

United States
National Cancer Institute (NCI)

Terminated

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | Lymphoma, Non-hodgkins | B-Cell Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

Leukemia | B Cell Lymphoma | Non-Hodgkin Lymphoma | ALL | Large Cell Lymphoma

United States
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain
Affini-T Therapeutics, Inc.

Recruiting

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Colorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Pancreatic Ductal Adenocarcinoma | KRAS G12V

United States
National Institute of Allergy and Infectious Diseases...
University of Pennsylvania Clinical Cell and Vaccine Production Facility...

Recruiting

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Kidney Failure | End Stage Renal Failure on Dialysis | Kidney Transplant

United States
Juventas Cell Therapy Ltd.

Not yet recruiting

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (B-ALL)

B-cell Acute Lymphoblastic Leukemia
Vor Biopharma

Recruiting

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Leukemia, Myeloid, Acute

United States
CARGO Therapeutics

Recruiting

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma (FIRCE-1)

Cancer | Relapsed/Refractory Large B-cell Lymphoma (LBCL)

United States
Myeloid Therapeutics

Recruiting

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony)

Epithelial Tumors, Malignant

Australia
Kai Lin Xu，MD
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

Neoplasms | Hematologic Diseases | Hematologic Neoplasms

China
Memorial Sloan Kettering Cancer Center
Takeda

Recruiting

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

B-Cell Lymphoma | Large B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | Mediastinal Large B-cell Lymphoma | High-grade B Cell Lymphoma

United States
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Hematologic Cancer

United States, Israel, Japan
Christian Hinrichs

Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical Cancer | HPV-Related Malignancy | Metastatic Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditions

United States
Legend Biotech USA Inc

Recruiting

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage | Large Cell Neuroendocrine Carcinoma of the Lung

United States
Juventas Cell Therapy Ltd.

Recruiting

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

B-cell Acute Lymphoblastic Leukemia

China
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Nektar Therapeutics

Recruiting

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Non-Hodgkin Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma

United States
Cellectis S.A.

Recruiting

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01)

B-cell Non-Hodgkin Lymphoma (B-NHL)

United States, Spain, France
Fate Therapeutics

Recruiting

FT576 in Subjects With Multiple Myeloma

Multiple Myeloma | Myeloma

United States
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Multiple Myeloma

China
Nkarta Inc.

Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Lymphoma, Non-Hodgkin | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | B-cell Acute Lymphoblastic Leukemia | Small Lymphocytic Lymphoma | Large B-cell Lymphoma | Indolent Lymphoma | Aggressive Lymphoma | Large-cell Lymphoma

United States, Australia
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); Baylor College of Medicine; Texas Children's... and other collaborators

Recruiting

HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

Ependymoma

United States
Miltenyi Biomedicine GmbH

Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

Central Nervous System Lymphoma | Transformed Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL) | Relapsed Diffuse Large B Cell Lymphoma

United States
Cabaletta Bio

Recruiting

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Pemphigus Vulgaris

United States
University of Kansas Medical Center
Seagen Inc.

Recruiting

Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T)

T Cell Lymphoma

United States
Cellectis S.A.

Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

B-cell Acute Lymphoblastic Leukemia

United States, France
Cartesian Therapeutics

Recruiting

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Myasthenia Gravis, Generalized

United States, Canada
Malaghan Institute of Medical Research
Wellington Zhaotai Therapies Limited

Active, not recruiting

ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) (ENABLE)

Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Lymphomas Non-Hodgkin's B-Cell | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL)

New Zealand
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital

Active, not recruiting

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Relapsed B-Cell Acute Lymphoblastic Leukemia

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Non-Hodgkin's Lymphoma

United States
Takeda

Active, not recruiting

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

United States
Juno Therapeutics, a Subsidiary of Celgene

Completed

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)

Multiple Myeloma

United States
Novartis Pharmaceuticals

Active, not recruiting

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Saudi Arabia, Germany, Singapore, Italy, France, Israel, United Kingdom, Japan, Australia, Spain, Brazil, United States, Greece, Canada
Juno Therapeutics, a Subsidiary of Celgene

Completed

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma Non-Hodgkin | Agressive Lymphoma | Diffuse-large B-cell Lymphoma (DLBCL)

United States, Canada
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET)

Diffuse Large B-cell Lymphoma (DLBCL)

United States, Japan, Australia, Italy, Canada, Germany, Norway, Netherlands, France, Austria
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Follicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell Lymphoma

United States
Instil Bio

Active, not recruiting

ITIL-306 in Advanced Solid Tumors

Renal Cell Carcinoma | Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

United States
Kite, A Gilead Company
Humanigen, Inc.

Terminated

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19)

Relapsed/Refractory Large B-cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Active, not recruiting

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
Novartis Pharmaceuticals

Available

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Acute Lymphoblastic Leukemia (ALL) | Diffuse Large B-cell Lymphoma (DLBCL)

United States, Canada, Australia
Juno Therapeutics, a Subsidiary of Celgene

Completed

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Nonhodgkin

United States
Juno Therapeutics, a Subsidiary of Celgene
Bristol-Myers Squibb

Completed

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Neoplasms | Neoplasms by Histologic Type | Lymphoma | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin | Immune System Disorder

United States
Dartmouth-Hitchcock Medical Center

Completed

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG (FluBuATG)

Myelodysplastic Syndromes | Leukemia, Myeloid | Multiple Myeloma | Lymphoma, Malignant | Myelofibrosis | Waldenstrom Macroglobulinemia | Leukemia, Lymphoid

United States
Tceleron Therapeutics, Inc.

Terminated

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
United States Department of Defense

Active, not recruiting

T-Cell Therapy for Advanced Breast Cancer

Breast Cancer | Metastatic HER2-negative Breast

United States

Search clinical trials for: New Cluster of Differentiation Antigen 19-chimeric Antigen Receptor T Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations